Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes - Wikidata - wikimedia - TriplyDB

Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes

Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes

http://www.wikidata.org/entity/Q33751549

about

Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience Immunotherapy in autoimmune type 1 diabetes Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Immune therapy in type 1 diabetes mellitus Type 1 diabetes: translating mechanistic observations into effective clinical outcomes Type 1 diabetes mellitus.Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data Efforts to prevent and halt autoimmune beta cell destruction.Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes.Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.Stem cell treatment for type 1 diabetes.Progressive erosion of β-cell function precedes the onset of hyperglycemia in the NOD mouse model of type 1 diabetes.Immune therapy for treating type 1 diabetes: challenging existing paradigms.Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.Central role for interleukin-2 in type 1 diabetes.Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil Paediatric use of mycophenolate mofetil.Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth.Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome Type 1 diabetes: etiology, immunology, and therapeutic strategies.GAD-alum immunotherapy in Type 1 diabetes mellitus.Immune and cell therapy in type 1 diabetes: too little too late?DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes.Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus.Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes.Risks, benefits, and therapeutic potential of hematopoietic stem cell transplantation for autoimmune diabetes.Clinical immunologic interventions for the treatment of type 1 diabetes.Progress in immune-based therapies for type 1 diabetes.Targeted immune interventions for type 1 diabetes: not as easy as it looks!Trials in the prevention of type 1 diabetes: current and future Combination immunotherapies for type 1 diabetes mellitus.Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes.Less is more: the detrimental consequences of immunosuppressive therapy in the treatment of type-1 diabetes.Combination Immunotherapy for Type 1 Diabetes.

P2860

Q26850621-9233E357-A644-44D6-8631-E057DCA1C1EB Q27025619-EB7C3C63-DEAB-47B1-8E15-BCB829F5AA5E Q27687598-FB618187-41AC-403D-A3CD-BFBBFB1455C9 Q28081034-42108EF7-E746-479D-8327-C82E4726E8B8 Q28282846-87DCCC04-B5EF-417B-A686-E31D92255A13 Q28287737-3DBAE7CC-E057-4C2C-B62D-5BE11C013E77 Q30235021-6B384792-3166-41C5-9577-E58CB582E57A Q30521476-E67D3D80-DB97-475D-AC7B-5842CD42F7A8 Q34077363-82C3E995-C4B8-412A-B0A0-A9DF4B127D9B Q34079225-3DBFD14B-622F-4D0A-9AF5-2DE5BEADAF60 Q34082782-96892024-2B17-4C4C-887E-9D48F189B68E Q34391021-84E859DD-6683-4FBB-83EA-EB56DCF80D79 Q35123531-B9ADF252-186E-41B3-8035-730282EC755A Q35242386-F1979E0E-5650-4FF9-91AC-FB4E4854D2B3 Q35242428-52D5C7F8-D538-46DA-B90F-9436FC35BE48 Q35612414-8ED0F26B-E4AA-4322-BBA4-F005E7873FD6 Q36077883-55AA3F21-6EFF-4628-BA37-732C94CF2B68 Q36182476-5F62F219-E58F-4249-8EE3-5BA545356382 Q36216535-4EDD2895-A876-4072-91FE-592450E4AFEE Q36477951-A778C935-6422-4322-B3EC-E4AC8A4FE6DE Q36562448-6A6EA42F-1914-4C4E-A9F1-BE6833E13441 Q36632019-B82250D8-44E2-49DA-B8EF-B042C299C6F2 Q36749719-28367A9B-CDB7-4FCA-BE1F-0DEA581F443D Q36913132-6A0A8013-930E-45AA-8D91-A9D6D7907565 Q37088225-66481D1F-EEC0-4A30-9801-3E826AA9E68B Q37830198-E962C7D7-8628-413C-92D3-3C356FA9BA9E Q37851966-8961FE95-45AB-404C-8C4E-F505A89DFCF8 Q37853194-1123FAD2-FE5D-414C-AD39-01B2DEBFCF66 Q37900639-AB3F39E8-A4F8-4428-AB2D-3ADC489EDFB2 Q37931276-0071D887-CD57-49A0-B826-7260009CAA0E Q38012381-EA955B5E-0DA9-4D8F-8728-10F479D0E456 Q38032163-F6BF4EDF-C160-42A4-AD71-38FFD8C1A493 Q38036230-6724F0DC-79EE-47D7-A376-CD824F5CFFA6 Q38097920-ACB80CFD-9D59-489C-ADB5-45799A64A78A Q38225173-EF395A47-2D98-41A2-8882-18DE955A2D91 Q38237031-F7E9C2B3-BF10-457B-B089-EF4D0D020E18 Q38358009-8177B9F4-8CD3-4A50-B089-295638E3B32E Q38384138-8A74A4F9-3950-40C4-A8E7-4F60CDF2ED0C Q38385236-7912B4E0-F393-4242-93D1-02DFC7AF3E16 Q38680333-70CB4C5B-F23D-48A0-A01C-17C0FE7296E6

P2860

Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes

http://www.wikidata.org/entity/Q33751549

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Failure to preserve beta-cell ...... ith new- onset type 1 diabetes

@ast

Failure to preserve beta-cell ...... ith new- onset type 1 diabetes

@en

type

label

Failure to preserve beta-cell ...... ith new- onset type 1 diabetes

@ast

Failure to preserve beta-cell ...... ith new- onset type 1 diabetes

@en

prefLabel

Failure to preserve beta-cell ...... ith new- onset type 1 diabetes

@ast

Failure to preserve beta-cell ...... ith new- onset type 1 diabetes

@en

P1433

Q33751549-6183D191-45FF-45C5-A6E2-8F7FA3D7CD47

P1476

Q33751549-D60E3953-8A8F-4577-A94C-6C785BB3DEB1

P2093

Q33751549-1A8D1FC4-8558-483C-9B2C-0682B7A0F584

Q33751549-3DBCDC36-A3FC-4835-B914-B1C291ECC05A

Q33751549-49518682-9328-4090-9D9D-6548846C6F15

Q33751549-5264880C-FD0D-4CC7-B574-8860D23B05C2

Q33751549-640D0595-AC03-41A3-922F-E16E781ED5DC

Q33751549-70D75EC9-CA94-42CE-B661-00B56B5B5235

Q33751549-A4002F96-D952-4142-8CD7-A0490225B79B

Q33751549-DF1A604C-2254-451C-B712-41BB120E4301

Q33751549-EBED9E79-E49F-4A65-BBD6-EFFB2EF40E2D

Q33751549-F00B7291-4D5D-4772-A1DF-F65DBE2D01DA

P2860

Q33751549-014F3C3D-245A-464D-BFDA-65E4BCC5D156

Q33751549-0C9164B4-5F05-4934-A15B-04620C17B57B

Q33751549-37C605D5-C809-4542-B724-0854EEF8D2F5

Q33751549-42B8760F-E040-43E2-B793-DF2C839725FE

Q33751549-60D6671D-CED8-4EE2-A306-A7E8FD8EE2A7

Q33751549-7054409F-7A48-4E9B-AA1D-ACFC43580265

Q33751549-7A4D15C1-9E26-436D-B490-0FDEE9124290

Q33751549-7D065ACE-B27E-439B-899F-195649C05697

Q33751549-841FA734-4D49-46BA-AB2A-1A1D62D55302

Q33751549-897A9453-B4B6-45AA-81C7-362D5F4D88A0

P304

Q33751549-00C5204F-89E6-41DB-B789-173C1C65DA52

P31

Q33751549-86590890-B664-43EF-A1E9-9399FB78408D

P356

Q33751549-BC891DA8-7C69-4E63-B291-40C7E0EEC728

P407

Q33751549-191721F1-C3C2-462C-BF87-A65A5FCB5888

P433

Q33751549-B282ADB8-4B70-4911-AD01-A23ABF17CD4B

P478

Q33751549-8FFC7276-7863-4B5B-BB99-5FF697AC002C

P50

Q33751549-4DD846D5-EBC0-460C-9E93-C989652B90ED

P577

Q33751549-5032EC46-6DDE-4EE6-B67F-7605071091F2

P5875

Q33751549-B3477A9D-FB8F-473E-8C23-89115B9E1702

P698

Q33751549-271CAEFD-A561-40F7-BE5D-8D13E2F1C055

P921

Q33751549-33E354C5-7B97-4901-98C5-F5EEF85C02C5

P932

Q33751549-FFDC0DA4-22EF-4C90-A38D-80EAC474A183

P356

P1433

P1476

Failure to preserve beta-cell ...... ith new- onset type 1 diabetes

@en

P2093

Antoinette M Moran

http://www.w3.org/2001/XMLSchema#string

Carla J Greenbaum

http://www.w3.org/2001/XMLSchema#string

Darrell M Wilson

http://www.w3.org/2001/XMLSchema#string

Desmond A Schatz

http://www.w3.org/2001/XMLSchema#string

Heidi Krause-Steinrauf

http://www.w3.org/2001/XMLSchema#string

Henry Rodriguez

http://www.w3.org/2001/XMLSchema#string

Jay S Skyler

http://www.w3.org/2001/XMLSchema#string

Peter A Gottlieb

http://www.w3.org/2001/XMLSchema#string

Scott Quinlan

http://www.w3.org/2001/XMLSchema#string

Type 1 Diabetes TrialNet MMF/DZB Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen

Type 1 Diabetes TrialNet--an international collaborative clinical trials network

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

GAD treatment and insulin secretion in recent-onset type 1 diabetes.

Immunotherapeutic approaches to prevent, ameliorate, and cure type 1 diabetes.

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety.

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

P304

826-832

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC09-1349

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41000625

http://www.w3.org/2001/XMLSchema#string

P698

20067954

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

2845036

http://www.w3.org/2001/XMLSchema#string